The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Humira Biosimilar Market Research Report 2024

Global Humira Biosimilar Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739053

No of Pages : 94

Ask Your Query

Synopsis
Humira is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Global Humira Biosimilar market is projected to reach US$ 958.9 million in 2029, increasing from US$ 421 million in 2022, with the CAGR of 12.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Humira Biosimilar market research.

The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Humira Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Cadila Healthcare
  • Torrent Pharmaceuticals
  • Amgen
  • Boehringer Ingelheim
  • Novartis
  • Samsung Bioepis
  • Viatris
  • Pfizer
  • Fresenius Kabi
  • Coherus

Segment by Type

  • Syringe
  • Pen

Segment by Application

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Humira Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Humira Biosimilar Market Overview
1.1 Product Overview and Scope of Humira Biosimilar
1.2 Humira Biosimilar Segment by Type
1.2.1 Global Humira Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Syringe
1.2.3 Pen
1.3 Humira Biosimilar Segment by Application
1.3.1 Global Humira Biosimilar Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Humira Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Humira Biosimilar Revenue 2018-2029
1.4.2 Global Humira Biosimilar Sales 2018-2029
1.4.3 Global Humira Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Humira Biosimilar Market Competition by Manufacturers
2.1 Global Humira Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Humira Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Humira Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Humira Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Humira Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Humira Biosimilar, Product Type & Application
2.7 Humira Biosimilar Market Competitive Situation and Trends
2.7.1 Humira Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Humira Biosimilar Players Market Share by Revenue
2.7.3 Global Humira Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Humira Biosimilar Retrospective Market Scenario by Region
3.1 Global Humira Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Humira Biosimilar Global Humira Biosimilar Sales by Region: 2018-2029
3.2.1 Global Humira Biosimilar Sales by Region: 2018-2023
3.2.2 Global Humira Biosimilar Sales by Region: 2024-2029
3.3 Global Humira Biosimilar Global Humira Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Humira Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Humira Biosimilar Revenue by Region: 2024-2029
3.4 North America Humira Biosimilar Market Facts & Figures by Country
3.4.1 North America Humira Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Humira Biosimilar Sales by Country (2018-2029)
3.4.3 North America Humira Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Humira Biosimilar Market Facts & Figures by Country
3.5.1 Europe Humira Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Humira Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Humira Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Humira Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Humira Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Humira Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Humira Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Humira Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Humira Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Humira Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Humira Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Humira Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Humira Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Humira Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Humira Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Humira Biosimilar Sales by Type (2018-2029)
4.1.1 Global Humira Biosimilar Sales by Type (2018-2023)
4.1.2 Global Humira Biosimilar Sales by Type (2024-2029)
4.1.3 Global Humira Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Humira Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Humira Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Humira Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Humira Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Humira Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Humira Biosimilar Sales by Application (2018-2029)
5.1.1 Global Humira Biosimilar Sales by Application (2018-2023)
5.1.2 Global Humira Biosimilar Sales by Application (2024-2029)
5.1.3 Global Humira Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Humira Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Humira Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Humira Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Humira Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Humira Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Cadila Healthcare
6.1.1 Cadila Healthcare Corporation Information
6.1.2 Cadila Healthcare Description and Business Overview
6.1.3 Cadila Healthcare Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Cadila Healthcare Humira Biosimilar Product Portfolio
6.1.5 Cadila Healthcare Recent Developments/Updates
6.2 Torrent Pharmaceuticals
6.2.1 Torrent Pharmaceuticals Corporation Information
6.2.2 Torrent Pharmaceuticals Description and Business Overview
6.2.3 Torrent Pharmaceuticals Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Torrent Pharmaceuticals Humira Biosimilar Product Portfolio
6.2.5 Torrent Pharmaceuticals Recent Developments/Updates
6.3 Amgen
6.3.1 Amgen Corporation Information
6.3.2 Amgen Description and Business Overview
6.3.3 Amgen Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Amgen Humira Biosimilar Product Portfolio
6.3.5 Amgen Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim Humira Biosimilar Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis Humira Biosimilar Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Corporation Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Samsung Bioepis Humira Biosimilar Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Viatris
6.6.1 Viatris Corporation Information
6.6.2 Viatris Description and Business Overview
6.6.3 Viatris Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Viatris Humira Biosimilar Product Portfolio
6.7.5 Viatris Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Pfizer Humira Biosimilar Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Fresenius Kabi
6.9.1 Fresenius Kabi Corporation Information
6.9.2 Fresenius Kabi Description and Business Overview
6.9.3 Fresenius Kabi Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Fresenius Kabi Humira Biosimilar Product Portfolio
6.9.5 Fresenius Kabi Recent Developments/Updates
6.10 Coherus
6.10.1 Coherus Corporation Information
6.10.2 Coherus Description and Business Overview
6.10.3 Coherus Humira Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Coherus Humira Biosimilar Product Portfolio
6.10.5 Coherus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Humira Biosimilar Industry Chain Analysis
7.2 Humira Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Humira Biosimilar Production Mode & Process
7.4 Humira Biosimilar Sales and Marketing
7.4.1 Humira Biosimilar Sales Channels
7.4.2 Humira Biosimilar Distributors
7.5 Humira Biosimilar Customers
8 Humira Biosimilar Market Dynamics
8.1 Humira Biosimilar Industry Trends
8.2 Humira Biosimilar Market Drivers
8.3 Humira Biosimilar Market Challenges
8.4 Humira Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock